Cargando…

Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis

BACKGROUND: We assessed the cost-effectiveness of adding a quadrivalent (6/11/16/18) human papillomavirus (HPV) vaccine to the current screening programme in the UK compared to screening alone. METHODS: A Markov model of the natural history of HPV infection incorporating screening and vaccination wa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kulasingam, Shalini L, Benard, Steve, Barnabas, Ruanne V, Largeron, Nathalie, Myers, Evan R
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2290741/ https://www.ncbi.nlm.nih.gov/pubmed/18279515 http://dx.doi.org/10.1186/1478-7547-6-4

Ejemplares similares

Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis
por: Kulasingam, Shalini L, et al.
Publicado: (2009)

The Cost-Effectiveness of Quadrivalent Human Papillomavirus Vaccination in Indonesia
por: Kosen, Soewarta, et al.
Publicado: (2017)

Cost-Utility of a Two-Dose Human Papillomavirus Vaccination Programme Added to Cervical Cancer Screening Compared with Cervical Cancer Screening Alone in Korea
por: Lee, Hyunju, et al.
Publicado: (2019)

Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe
por: Uhart, Mathieu, et al.
Publicado: (2016)

Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy
por: Rossi, Paolo Giorgi, et al.
Publicado: (2009)

Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia
por: Crowe, Elizabeth, et al.
Publicado: (2014)

Women's perspectives on human papillomavirus self‐sampling in the context of the UK cervical screening programme
por: Williams, Denitza, et al.
Publicado: (2017)

Systematic review of cost-effectiveness analyses for combinations of prevention strategies against human papillomavirus (HPV) infection: a general trend
por: Gervais, Frédéric, et al.
Publicado: (2017)

An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme
por: Sherlaw-Johnson, C, et al.
Publicado: (2004)

Cost of community-based human papillomavirus self-sampling in Peru: A micro-costing study
por: Shin, Michelle B., et al.
Publicado: (2021)

Test Performance of Cervical Cytology Among Adults With vs Without Human Papillomavirus Vaccination
por: Teoh, Deanna, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of the Bivalent and Quadrivalent Human Papillomavirus Vaccines from a Societal Perspective in Colombia
por: Aponte-González, Johanna, et al.
Publicado: (2013)

Health care personnel’s perspectives on human papillomavirus (HPV) self-sampling for cervical cancer screening: a pre-implementation, qualitative study
por: Xiong, Serena, et al.
Publicado: (2022)

Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico
por: Ortiz, Ana Patricia, et al.
Publicado: (2017)

The epidemiologic and economic impact of a quadrivalent human papillomavirus vaccine in Thailand
por: Termrungruanglert, Wichai, et al.
Publicado: (2021)

Prevention of cervical, vaginal, and vulval cancers: role of the quadrivalent human papillomavirus (6, 11, 16, 18) recombinant vaccine
por: Diaz, Maria Lina
Publicado: (2010)

Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary
por: Vokó, Zoltán, et al.
Publicado: (2012)

Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination
por: Östensson, Ellinor, et al.
Publicado: (2015)

A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil(®))
por: Govan, Vandana A
Publicado: (2008)

Quadrivalent Human Papillomavirus Vaccine Effectiveness: A Swedish National Cohort Study
por: Leval, Amy, et al.
Publicado: (2013)

The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia
por: Uusküla, Anneli, et al.
Publicado: (2013)

Correction: Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico
por: Ortiz, Ana Patricia, et al.
Publicado: (2018)

Quadrivalent Human Papillomavirus Vaccine Effectiveness after 12 Years in Madrid (Spain)
por: Hernandez-Aguado, Juan J., et al.
Publicado: (2022)

A case of acute disseminated encephalomyelitis following human papillomavirus quadrivalent vaccination
por: Lee, Mina, et al.
Publicado: (2022)

Does the HPV vaccination programme have implications for cervical screening programmes in the UK?()
por: Beer, Helen, et al.
Publicado: (2014)

Geospatial patterns of human papillomavirus vaccine uptake in Minnesota
por: Nelson, Erik J, et al.
Publicado: (2015)

Lower human papillomavirus vaccine initiation and completion among Asian American adolescents compared to their peers: National Health and Nutritional Examination Survey 2011–2018
por: Zhao, Ran, et al.
Publicado: (2023)

Cost-effectiveness for high dose quadrivalent versus the adjuvanted quadrivalent influenza vaccine in the Italian older adult population
por: Rumi, Filippo, et al.
Publicado: (2023)

Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data
por: Joura, Elmar A, et al.
Publicado: (2012)

Cost–effectiveness analysis of quadrivalent influenza vaccine in Spain
por: García, Amos, et al.
Publicado: (2016)

From cervical cancer elimination to eradication of vaccine-type human papillomavirus: Feasibility, public health strategies and cost-effectiveness
por: Jit, Mark, et al.
Publicado: (2021)

Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model
por: Jit, Mark, et al.
Publicado: (2011)

Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity
por: Brady, Allison M., et al.
Publicado: (2020)

Human papillomavirus (HPV) in young women in Britain: Population-based evidence of the effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types
por: Tanton, Clare, et al.
Publicado: (2017)

The Potential Cost-Effectiveness of HIV Vaccines: A Systematic Review
por: Adamson, Blythe, et al.
Publicado: (2017)

Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria
por: Boiron, L., et al.
Publicado: (2016)

Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England
por: Thorrington, Dominic, et al.
Publicado: (2017)

The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom
por: Kohli, Michele A., et al.
Publicado: (2021)

Cost effectiveness of quadrivalent influenza vaccines in the elderly population of Malaysia
por: Aljunid, Syed Mohamed, et al.
Publicado: (2023)

A case–control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events
por: Geier, David A., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5bjmjgiuci72gunq85sm00l36q